$2, page-20

Because no one has access to the data in the first part of the Phase III trial, I doubt whether a USA deal will eventuate anytime soon. Would a US company jump in based on a generic recommendation to proceed to the next trial stage? Would they not want to see some hard data?

From what Nina has said about the respective regulatory authorities, I think a China deal is more likely to happen first but who knows how long that would take to organise.

The final readout will be met with great anticipation, but with a very long wait until the final results, I expect the share price to sit quietly for quite a while.

Just my thoughts. As always, I won't turn down unexpected great news.